| Trial ID: | L0350 |
| Source ID: | NCT04702490
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
|
| Acronym: |
--
|
| Status: |
Active, not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH|NASH - Nonalcoholic Steatohepatitis|Type 2 Diabetes|Diabetes Type 2|Diabetes|Fatty Liver|Fatty Liver, Nonalcoholic|NAFLD
|
| Interventions: |
Drug: MET409 Active|Drug: MET409 Placebo|Drug: Empagliflozin
|
| Outcome Measures: |
Safety and tolerability of MET409 with or without empagliflozin (incidence of adverse events)|Pharmacological activity of MET409 alone or in combination with empagliflozin|Pharmacokinetic profile of MET409 alone or in combination with empagliflozin|Pharmacodynamic profile of MET409 alone or in combination with empagliflozin
|
| Sponsor/Collaborators: |
Metacrine, Inc.
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
120
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
December 15, 2020
|
| Completion Date: |
June 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
June 1, 2021
|
| Locations: |
Metacrine Investigative Site, Fort Myers, Florida, United States|Metacrine Investigative Site, San Antonio, Texas, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04702490
|
